Amanda Henry, APRN
Adult Health · Oklahoma City, OKNPI 1174202485
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 30 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 12 manufacturers, the largest accounting for just 19.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $460 and has fallen 90.8% since, to $43 in 2025.
Across 30 payments — averaging $23.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$134
- Argenx US, Inc.$120
- Acadia Pharmaceuticals Inc$88
- Teva Pharmaceuticals USA, Inc.$78
- Merz Pharmaceuticals, LLC$54
- SK Life Science, Inc.$51
- plus $166 from 6 others
What the payments were for
- Food & beverage$691100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 5 | $134 |
| Argenx US, Inc. | 5 | $120 |
| Acadia Pharmaceuticals Inc | 4 | $88 |
| Teva Pharmaceuticals USA, Inc. | 3 | $78 |
| Merz Pharmaceuticals, LLC | 3 | $54 |
| SK Life Science, Inc. | 2 | $51 |
| AstraZeneca | 2 | $51 |
| Lundbeck LLC | 2 | $41 |
| TG Therapeutics, Inc. | 1 | $24 |
| Livanova USA, Inc. | 1 | $21 |
| Pfizer | 1 | $17 |
| UCB, Inc. | 1 | $13 |
How this compares
$691 in reported general payments places this provider in the 55th percentile of 117 adult health providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gabapentin | 38 | $659 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 23 | $432 |
| Hydroxyzine Hcl | 11 | $296 |
| Donepezil Hcl | 20 | $255 |
| Topiramate | 22 | $216 |
| Levetiracetam | 12 | $178 |
| Pramipexole DihydrochloridePramipexole Di-Hcl | 15 | $134 |
Paid to pharmacies, not to this prescriber.
Other adult health in Oklahoma City
- Cynthia CattaneoOklahoma City$45K
- Miki ThompsonOklahoma City$14K
- Kellie RohwerOklahoma City$11K
- Terry GreenOklahoma City$9K
- Nissy PhilipOklahoma City$8K
- Alexis StinnettOklahoma City$6K
- Michael EskewOklahoma City$5K
- Candace BeckerOklahoma City$5K
- Anna CottleOklahoma City$5K
- Tyler AgeeOklahoma City$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.